Alemtuzumab

Red

Brand Name(s):Lemtrada

Indication:Multiple sclerosis relapsing remitting (RRMS) in adults with active disease defined by clinical or imaging features

Rationale:1,2,8

Considered:Jul-13

Review Date:Jan-25

Comments:
The restrictions on the use of alemtuzumab to certain patient groups, have now been endorsed by Committee for Medicinal Products for Human Use (CHMP). Nov 19.
LINK; https://www.ema.europa.eu/en/medicines/human/referrals/lemtrada
LINK; https://www.ema.europa.eu/en/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis_en.pdf

Drug Safety Update
Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions: new restrictions to use and strengthened monitoring requirements
May 2019 ………………………… NICE CG186 Management of MS in Primary & Secondary Care:
http://www.nice.org.uk/guidance/cg186/resources/guidance-multiple-sclerosis-pdf
Oct 2014